Meriwether D, Sulaiman D, Volpe C, Dorfman A, Grijalva V, Dorreh N, Solorzano-Vargas RS, Wang J, O'Connor E, Papesh J, Larauche M, Trost H, Palgunachari MN, Anantharamaiah GM, Herschman HR, Martin MG, Fogelman AM, Reddy ST (2019) <br />Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model<br /><i>J Clinical Investigation</i> <b>129</b>: 3670<br /><br />Li R, Navab M, Pakbin P, Ning Z, Navab K, Hough G, Morgan TE, Finch CE, Araujo JA, Fogelman AM, Sioutas C, Hsiai T (2013) <br />Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice<br /><i>J Lipid Res</i> <b>54</b>: 1608<br /><br />Yin F, Lawal A, Ricks J, Fox JR, Larson T, Navab M, Fogelman AM, Rosenfeld ME, Araujo JA (2013) <br />Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein<br /><i>Arterioscler Thromb Vasc Biol</i> <b>33</b>: 1153<br /><br />Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman AM (2012) <br />D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice<br /><i>J Lipid Res</i> <b>53</b>: 437<br /><br />Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, Fogelman AM, Navab M (2011) <br />Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease<br /><i>J Natl Med Assoc</i> <b>103</b>: 524<br /><br />Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, Navab M, Hama S, Hough G, Reddy ST, Soffer D, Rader DJ, Fogelman AM, Schecter A (2011) <br />Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function<br /><i>J Lipid Res</i> <b>52</b>: 361<br /><br />Reddy ST, Devarajan A, Bourquard N, Shih DM, Fogelman AM (2008) <br />Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?<br /><i>Curr Opin Lipidol</i> <b>19</b>: 405<br /><br />Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, Navab M, Fogelman AM, Reddy ST (2007) <br />A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors<br /><i>Prostaglandins Other Lipid Mediat</i> <b>84</b>: 24<br /><br />Ng CJ, Bourquard N, Hama SY, Shih DM, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2007) <br />Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice<br /><i>Arterioscler Thromb Vasc Biol</i> <b>27</b>: 1368<br /><br />Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman AM, Lusis AJ, Reddy ST (2007) <br />Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice<br /><i>Circulation Research</i> <b>100</b>: 1200<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM (2006) <br />Mechanisms of disease: proatherogenic HDL--an evolving field<br /><i>Nat Clin Pract Endocrinol Metab</i> <b>2</b>: 504<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM (2006) <br />Potential clinical utility of high-density lipoprotein-mimetic peptides<br /><i>Curr Opin Lipidol</i> <b>17</b>: 440<br /><br />Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST (2006) <br />Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2<br /><i>Journal of Biological Chemistry</i> <b>281</b>: 29491<br /><br />Reddy ST, Anantharamaiah GM, Navab M, Hama S, Hough G, Grijalva V, Garber DW, Datta G, Fogelman AM (2006) <br />Oral amphipathic peptides as therapeutic agents<br /><i>Expert Opin Investig Drugs</i> <b>15</b>: 13<br /><br />Van Lenten BJ, Reddy ST, Navab M, Fogelman AM (2006) <br />Understanding changes in high density lipoproteins during the acute phase response<br /><i>Arterioscler Thromb Vasc Biol</i> <b>26</b>: 1687<br /><br />Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM (2005) <br />D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice<br /><i>Arterioscler Thromb Vasc Biol</i> <b>25</b>: 1426<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM (2005) <br />Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice<br /><i>Circulation Research</i> <b>97</b>: 524<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM (2005) <br />Apolipoprotein A-I mimetic peptides<br /><i>Arterioscler Thromb Vasc Biol</i> <b>25</b>: 1325<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, Palgunachari MN, Fogelman AM (2005) <br />An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice<br /><i>Arterioscler Thromb Vasc Biol</i> <b>25</b>: 1932<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM (2004) <br />Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice<br /><i>Circulation</i> <b>109</b>: 3215<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM (2004) <br />Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal<br /><i>Curr Opin Lipidol</i> <b>15</b>: 645<br /><br />Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2004) <br />Apparent paradox of low-fat healthy diets increasing plasma levels of oxidized low-density lipoprotein and lipoprotein(a)<br /><i>Arterioscler Thromb Vasc Biol</i> <b>24</b>: 392<br /><br />Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Hough G, Wagner A, Nakamura K, Garber DW, Datta G, Segrest JP, Hama S, Fogelman AM (2003) <br />Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis<br /><i>Curr Opin Investig Drugs</i> <b>4</b>: 1100<br /><br />Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) <br />Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein<br /><i>Journal of Biological Chemistry</i> <b>276</b>: 44444<br /><br />Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) <br />Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids<br /><i>Arterioscler Thromb Vasc Biol</i> <b>21</b>: 542<br /><br />Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM (2000) <br />Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3<br /><i>J Lipid Res</i> <b>41</b>: 1495<br /><br />Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih DM, Fonarow GC (1998) <br />Paraoxonase and coronary heart disease<br /><i>Curr Opin Lipidol</i> <b>9</b>: 319<br /><br />Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) <br />Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis<br /><i>Nature</i> <b>394</b>: 284<br /><br />